George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
Possibly some profits from AGL coming over?
I'm sure there are more than a few people who hold both stocks.
Anyone with AJ Bell? My shares have appeared in my account but can't sold yet.
Any thoughts on the Golden cross that looks likely to occur in the next week?
The 50 day average will cross the 200 to the up side.
Following todays RNS from Threadneedle Asset Management:
As at 17 January 2022, Directors & Major Shareholders (that hold greater than 3.0%) are set out below:
Name No. of Ordinary Shares held Percentage of issued share capital
Crystal Amber Fund Limited 36,920,000 20.59%
Pembar Limited 24,889,833 13.88%
Jo Hambro Capital Management 12,000,000 6.69%
Schroders Funds 10,549,500 5.88%
Threadneedle Asset Management 9,017,652 5.03%
Stephen Heath 8,648,341 4.82%
Hargreaves Lansdown 7,589,414 4.23%
Christian Levett 7,069,344 3.93%
Totals 107,666,432 60.02%
In the Proactive interview Andrew Newland gave after the FDA submission he emphisises that there is an "inherent uncertainty" in the De Novo process time scale. H1 2021 was the earliest possible date.
Hopefully the FDA are running out of questions to ask.
Intresting comments from Andy Brough.
If it was a transfer from Crystal Amber, they will have dropped over 1% so we will find out in the next few days from another RNS.
They were previous holders. I looked at the IR website before it was updated and still have that page open. It says:
Schroders Funds 8,520,000 4.75%
After updating it says:
Schroders Funds 10,549,500 5.88%
so they have increased by 2 million shares.
Did the MM make a mistake this morning by opening so low? I wonder if they then got caught out, hence the rapid recovery.
The RNS didn't contain anything that should move the price. Supply issues are nothing new and are affecting every company and have no bearing on FDA approval.
The timescale for FDA approval is unknown and always has been, but we are likely nearer the end of the process than the beginning.
I was in IQAI when they were waiting for FDA approval for Stonechecker. They were badly delayed by the US government shutdown in early 2019.
I think the 90 day clock stopped when a question was asked and didn't start again until they were happy with the answer.
After the shut down no one knew what the timescale was anymore.
FDA was worth waiting for as it went from 4p to 15p in 2 days. It came back down as they had no idea how to commercialise it.
What he said was that the current holders will be diluted to infinity, ORPH holders will get 95% and the rest will be incentives for the new management team. That will include a new CEO and a new board recruited from outside of ORPH.
A 600k buy popped up at the close today. Wonder how long that took to fill. Didn't look like there was enough selling volume for a buy of that size.
On the day of FDA approval almost anything can happen. I have only been in one share before when FDA approval came in and that was IQAI when Stonechecker was approved. It did 150% on the day. There will be huge volume and trading.
Long term the share price will settle into a much higher range as it will open up the commercial pathways they have been seeking.
Others may know better, but I think they will then be the only company in the liquid biopsy space with FDA approval. That will be a significant moment.
I've seen a few references to the new CEO being part time. Is this confirmed and does anyone know what her salary is? I think Dan was on 120k or there abouts.
As for the down trend in the sp, it may actually have stabilized in the last 6 weeks. It's stopped making new lows since the placing. Far too early to say there is an uptrend but going sideways is an improvement.
I first found NFX in early 2019 and people have always talked about a seller. First it was Spreadex, then CPI then the 2 ex bods.
None of them are responsible for the 18 month downtrend in the sp. That is entirely down to NFX not making the progress we expected.
Lots of shares have a seller in them but if the company is executing well, the sp can rise dispite that.
It is on Proactive's youtube channel.
https://www.youtube.com/watch?v=H51LE6jEJ5c&t=4053s
Extremely good presentation. I would agree Andrew is looking very confident.
Labs capable of 50,000 samples per year, $1000 to $2000 per sample. Look foward to labs running at full capacity.
Interesting that someone asked about a takeover for £13 per share. Presumably because it's ten times current value. Andrew's not interested at that price.
The CFO then gave the example of Illumina aquiring Solexa for 600 million but went on to be worth 60 billion.
Hopefully if someone comes in with a low offer, share holders turn them down.
It is from the 18 Feb 2020 RNS appointing Keegan.
Soup, I would never normally doubt you but I thought Keegans warrents stretched to 2023. Was there a change?
From the RNS appointing Keegan:
"The Company has entered into an agreement with Karl whereby Karl will be issued with warrants to subscribe for 3,000,000 new ordinary shares of 0.1 pence in the capital of the Company conditional upon Karl continuing to act as Non-executive director of the Company on 17 February 2021 ("Warrants"). The Warrants are exercisable from 17 February 2021 to 17 February 2023, at an exercise price of 6.75 pence per ordinary share."
It's hard to belive that it has been 2 years since that glorious May 2019 when NXP001 passed it's trials and we thought £2.5million was incoming, Dan was going to negotiate ROW rights and Ebers was going to be worth up to £50 million.
No one could have imagined the 2 years that followed.
Also I would still like to see a TR1 from Dan to check if he is stil holding.
I don't hold HUR but have always followed it with interest.
I do however hold EQLS as do Crystal Amber. Their holdings increase RNS here in April came out at the same time as EQLS got a RNS showing a decrease of a similar amount.
Today another EQLS RNS showing a reduction last week so I wonder if they have been freeing cash to buy more here.
Looks like they've sold about £1.1 million.
It's risky on their part as EQLS are having a good year and HUR are clearly not.